192 related articles for article (PubMed ID: 26875154)
1. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens.
Veal GJ; Errington J; Sastry J; Chisholm J; Brock P; Morgenstern D; Pritchard-Jones K; Chowdhury T
Cancer Chemother Pharmacol; 2016 Apr; 77(4):685-92. PubMed ID: 26875154
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin therapeutic monitoring in preterm and full-term neonates.
Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.
Thomas F; Veal GJ; El Balkhi S; Lafont T; Picard N; Brugières L; Chatelut E; Piguet C
Cancer Chemother Pharmacol; 2018 Aug; 82(2):361-365. PubMed ID: 29922990
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma.
Picton SV; Keeble J; Holden V; Errington J; Boddy AV; Veal GJ
Cancer Chemother Pharmacol; 2009 Mar; 63(4):749-52. PubMed ID: 18607591
[TBL] [Abstract][Full Text] [Related]
5. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.
Barnett S; Hellmann F; Parke E; Makin G; Tweddle DA; Osborne C; Hempel G; Veal GJ
Eur J Cancer; 2022 Mar; 164():127-136. PubMed ID: 34657763
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.
Nijstad AL; Barnett S; Lalmohamed A; Bérénos IM; Parke E; Carruthers V; Tweddle DA; Kong J; Zwaan CM; Huitema ADR; Veal GJ
Eur J Cancer; 2022 Mar; 164():137-154. PubMed ID: 34865945
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy.
Veal GJ; English MW; Grundy RG; Shakespeare C; Glaser A; Waters F; Holden V; O'Meara A; Michalski A; Howe K; Cole S; Boddy AV
Cancer Chemother Pharmacol; 2004 Oct; 54(4):295-300. PubMed ID: 15133627
[TBL] [Abstract][Full Text] [Related]
8. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom.
Barnett S; Kong J; Makin G; Veal GJ
Br J Clin Pharmacol; 2021 Feb; 87(2):256-262. PubMed ID: 32519769
[TBL] [Abstract][Full Text] [Related]
9. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
10. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in newborns and preterm babies.
Veal GJ; Boddy AV
Semin Fetal Neonatal Med; 2012 Aug; 17(4):243-248. PubMed ID: 22464845
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.
Loh GW; Ting LS; Ensom MH
Clin Pharmacokinet; 2007; 46(6):471-94. PubMed ID: 17518507
[TBL] [Abstract][Full Text] [Related]
13. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
de Jongh FE; Verweij J; Loos WJ; de Wit R; de Jonge MJ; Planting AS; Nooter K; Stoter G; Sparreboom A
J Clin Oncol; 2001 Sep; 19(17):3733-9. PubMed ID: 11533095
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis.
Nijstad AL; van Eijkelenburg NKA; Kraal KCJM; Meijs MJM; de Kanter CTMM; Lilien MR; Huitema ADR
Cancer Chemother Pharmacol; 2020 Sep; 86(3):445-449. PubMed ID: 32816154
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
16. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.
Hutson JR; Weitzman S; Schechter T; Arceci RJ; Kim RB; Finkelstein Y
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):709-22. PubMed ID: 22509821
[TBL] [Abstract][Full Text] [Related]
18. Practical treatment guide for dose individualisation in cancer chemotherapy.
Canal P; Chatelut E; Guichard S
Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
[TBL] [Abstract][Full Text] [Related]
19. [Optimalisation of netilmicin dosage based on therapeutic drug monitoring during the first days of life in very preterm neonates (gestational age 23-32 weeks)].
Rutkowska M; Kamińska E; Piekarczyk A; Nowicka K; Polak K; Nowakowska-Szyrwińska E; Szamotulska K
Med Wieku Rozwoj; 2009; 13(4):252-9. PubMed ID: 20081273
[TBL] [Abstract][Full Text] [Related]
20. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
